We are live on ! Find out more
ACM

Athyrium Capital Management Portfolio holdings

AUM $8.69M
1-Year Est. Return 34.58%
This Fund
S&P 500
This Quarter Est. Return
-12.38%
1 Year Est. Return
-34.58%
3 Year Est. Return
-25.1%
5 Year Est. Return
10 Year Est. Return
AUM
$238M
AUM Growth
-$43.5M
Cap. Flow
-$109M
Cap. Flow %
-45.9%
Top 10 Hldgs %
99.26%
Holding
11
New
1
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 49.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$61.9M 26.04%
8,857,268
BIOR
2
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$20.9M 8.79%
119,423
CMAX
3
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$16.3M 6.85%
149,574
RVLP
4
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$11.1M 4.66%
8,148,832
PBYI icon
5
Puma Biotechnology
PBYI
$402M
$5.11M 2.15%
1,792,114
SCTL
6
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.75M 0.74%
2,202,420

Similar funds

Athyrium Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Athyrium Capital Management held 11 positions worth $238M, down 15% from $281M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Athyrium Capital Management withdrew a net $109M in Q2 2022.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 58% a quarter earlier.

  • Athyrium Capital Management's ten largest holdings make up 99% of its $238M portfolio in Q2 2022.
  • Athyrium Capital Management opened 1 new position and closed 0 in Q2 2022.
  • Athyrium Capital Management's portfolio value fell 15% quarter-over-quarter to $238M.

Based on Athyrium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.